Cyclooxygenase-2 (COX-2) plays a critical role in modulating deleterious actions of angiotensin II (Ang II) where there is an inappropriate activation of the renin-angiotensin system (RAS). This review discusses the recent developments regarding the complex interactions by which COX-2 modulates the impact of an activated RAS on kidney function and blood pressure.
INTRODUCTION
In addition to the beneficial effects of appropriate stimulation of the renin-angiotensin system (RAS) during reductions in sodium intake or extracellular fluid volume, an inappropriately activated RAS, particularly in the kidney, leads to hypertension and sodium retention caused by actions of Ang II on the renal microvasculature and sodium transport [1] . With sustained elevations in intrarenal RAS activity, elevated intrarenal Ang II levels synergize with various paracrine and cytokine factors leading to hypertension and renal injury eventually culminating in chronic kidney disease, diabetic nephropathy, and other renal diseases [2] . Without the presence of powerful counteracting protective mechanisms [3] , the degree of injury would possibly be much greater. This review is focused on the recent developments related to the roles of the metabolites of cyclooxygenase-2 (COX-2) in counteracting the deleterious actions of sustained increases in intrarenal Ang II [4, 5] . Much of our understanding of the interactions between Ang II and COX-2 metabolites has been derived from the patterns of COX-2 expression which are principally targeted by an augmented RAS activity leading to prostaglandin-mediated modulation of Ang II actions. Recent functional studies have questioned the firmly held notion that COX-2-derived prostanoids only counteract Ang II effects [6,7,8 & ] .
Prostaglandins are important mediators of renal vascular tone and sodium balance [9] , causing natriuresis because of both its vasodilatory action and inhibition of tubular Na þ reabsorption. The rate-limiting steps in the synthesis of prostaglandins are COX-1 and COX-2, which metabolize arachidonic acid to cyclic endoperoxides which are rapidly converted into prostaglandins and thromboxanes by tissue-specific isomerases (prostaglandin synthase) [10] . Agents that specifically block COX-1 or COX-2 have allowed delineation of their quantitative roles in modulating kidney function and blood pressure. COX-1 is termed 'constitutive', because it is normally expressed in a wide range of tissues. In kidneys, COX-1 is present along the distal tubule, and mediates the basal synthesis of prostaglandin E 2 (PGE 2 ) [11] . COX-2 is termed 'inducible', as stimuli that cause induction of COX-2 are associated with inflammation and cytokine production. However, COX-2 is also constitutively expressed in the kidneys [12] and is differentially regulated by Ang II via distinct actions of AT 1 and AT 2 receptors [13, 14] . The specific actions of COX-2 metabolites are determined by the restricted expression of COX-2 in cortex and medulla. In the cortex, COX-2 is constitutively expressed in the macula densa cells ( Fig. 1a ), which has led to the consideration of the roles of COX-2 in regulating tubuloglomerular feedback and renin release via PGE 2 [15] [16] [17] . COX-2 is also expressed in the epithelial cells of the thick limb of the ascending loop of Henle [16, 18] . In the medulla and papilla, COX-2 is expressed in interstitial cells [19] (Fig. 1b and c) .
COX-2 is differentially regulated in cortex and medulla. Sodium restriction augments cortical COX-2 expression and decreases medullary expression, whereas increased dietary salt leads to increased COX-2 in the inner medulla, but decreased cortical COX-2 expression. This divergent expression reflects distinct functions with medullary production contributing to salt and water reabsorption and medullary blood flow regulation, whereas cortical COX-2-derived prostaglandins modulate renin release and glomerular hemodynamics [14, 16] . Activation of the PGE 2 receptor, EP1, antagonizes the Ang II effects on aENaC expression in the inner
KEY POINTS
Low sodium diet and angiotensin-converting enzyme (ACE) inhibitors upregulate kidney cortical COX-2 activity, which elicits direct renoprotective or vasodilator influences independent of RAS activity but altered sodium excretion dependent on prevailing RAS activity.
In angiotensin-II-dependent hypertension, COX-2 metabolites (PGE 2 and PGI 2 ) exert vasodilator renoprotective functions, but other metabolites (Tx) exert a prohypertensive influence on systemic vascular resistance.
Renal medullary COX-2 maintains medullary perfusion during varying levels of cortical COX-2 and Ang II activities including normal and low salt diet, ACE inhibition, and hypertension.
COX-2 inhibition confers renal protection in diabetic rats, unmasking an underappreciated deleterious action of COX-2 in diabetes.
Emerging studies implicate oxidative stress in the transition from beneficial to deleterious glomerular actions of COX-2 in diabetes which leads to podocyte injury via a prorenin receptor-COX-2-EP4 receptor pathway. medulla and aldosterone-mediated upregulation of ENaC subunits [20] . EP1 receptors are present in afferent and efferent arterioles ( Fig. 1e ), but are more abundantly expressed in the inner medulla in normal conditions ( Fig. 1f ). Inhibition of COX-2 activity in the inner medulla leads to salt-sensitive hypertension [21] , indicating that COX-2 in the renal medulla exerts a key protective antihypertensive influence. COX-2 is increased in the inner medulla of Ang-II-infused rats but reduced in the cortex without changes in COX-1 ( Fig. 1d ) [20] . There is also augmented microsomal PGE 2 synthase-1 (mPGES-1) expression resulting in a PGE 2dependent reduction in sodium reabsorption [22 && ]. In aldosterone-infused rats, the initial decrease in sodium excretion wanes in parallel with augmented PGE 2 excretion, but persists in mPGES-1-deficient mice [20] .
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REGULATION OF RENIN RELEASE AND GLOMERULAR VASCULATURE BY COX-2-DEPENDENT PROSTANOIDS
COX-2 is a major regulator of renin release via the macula densa mechanism, in particular during sodium restriction [4, 14, 16, 23] . COX-2 is expressed in the macula densa cells [4, 24] linking macula densa sensing of sodium delivery to renin synthesis via activation of juxtaglomerular cell EP4 receptors to increase intracellular cAMP levels [4] . COX-2deficient mice have reduced plasma renin levels and renin expression, and reduced ability to respond to acute stimuli that normally increase renin secretion [25] . Decreases in luminal sodium concentration stimulate PGE 2 release to increase renin secretion, thus leading to increased Ang II formation [17, 26] . The effects on the microcirculation are less clear because PGE 2 may exert either afferent arteriolar vasodilation [27] or vasoconstriction [28] , whereas COX-2-derived thromboxane exerts vasoconstriction [29] . COX-2 contributes to adaptive responses in glomerular filtration rate (GFR) [30] . In a setting of elevated intrarenal Ang II levels, COX-1 products are predominantly vasoconstrictor, whereas COX-2 products elicit vasodilation [31 && ]. Ang-II-mediated augmentation of vascular tone is counterbalanced by COX-2 products, presumably PGE 2 . In addition, COX-2 mediates juxtaglomerular cell renin exocytosis in response to luminal hypotonicity [32] .
In contrast to the responses during sodium restriction, the increased plasma renin activity (PRA) subsequent to angiotensin-converting enzyme (ACE) inhibition is maintained, though significantly attenuated, during COX-2 inhibition [33] . Likewise, sympathetic nervous system activation of b 1 adrenergic receptors or blockade with isoproterenol has been disassociated from COX-2 effects on renin release [23, 34] . However, dopamine release by the sympathetic nervous system inhibits renin release via attenuation of COX-2 expression [35] . Overall, the extent to which cortical COX-2 promotes or attenuates Ang-II-mediated vasoconstriction is difficult to ascertain because the consequence of renin release is undefined relative to its potential to reduce renovascular resistance via PGE 2 production.
RENAL RESPONSES TO COX-2 INHIBITION IN RATS WITH VARYING STATES OF INTRARENAL ANG II ACTIVITY
Although experimental and clinical studies support the renoprotective role of COX-2 metabolites [36] , it has been difficult to delineate the actions of COX-2 prostanoids independent of the prevailing local RAS activity. Upregulated renocortical COX-2 expression is associated with increased vasodilatory influence during the augmented Ang II levels induced by sodium restriction [37, 38] . The minimal COX-2-mediated effect in the unperturbed kidney led to the speculation that prostaglandin effects depend on downmodulation of the augmented Ang-II-mediated vasoconstriction observed during sodium restriction. However, COX-2 expression is augmented by sodium restriction in both Sprague Dawley and hypertensive Ren-2 transgenic rats but shows no difference in hemodynamic influence despite greater Ang II in the latter [39] .
Two models of augmented COX-2 expression were recently studied to provide insight into the dependence of the effects of COX-2 inhibition on the prevailing intrarenal Ang II activity. The sodium restriction model has elevated COX-2 expression as well as augmented intrarenal Ang II activity, whereas the chronic ACE inhibition model has similar augmentation of cortical COX-2 activity but reduced intrarenal Ang II levels [40] . As shown in Fig. 2 , acute COX-2 inhibition with nimesulide in anesthetized rats subjected to chronic ACE inhibition and sodium restriction elicited similar decreases in GFR and renal plasma flow (RPF), thus offsetting any vasoconstrictive potential from renin release [40] . These results are consistent with those obtained during chronic COX-2 inhibition [38] and indicate that augmented cortical COX-2 promotes a vasodilatory influence on the renal microvasculature independent of the prevailing intrarenal RAS activity [41] . The responses in rats chronically treated with an ACE inhibitor were similar to those in sodium restricted rats and greater than those observed in rats on a normal salt diet. The responses in medullary blood flow were very similar in rats maintained on normal salt diet, low salt diet, or rats treated with ACE inhibitors, suggesting a tonic influence of COX-2 to protect medullary blood flow against excessive vasoconstriction under all conditions. COX-2 inhibition significantly reduced sodium excretion only in salt-restricted rats, indicating a dependence on prevailing Ang II activity. Although the effects of COX-2 inhibition on sodium excretion are contingent on RAS activity, they are apparently independent of the medullary blood flow responses.
COX-2 IN ANG-II-DEPENDENT HYPERTENSION
Another conundrum that has persisted is the functional contribution of COX-2 to the hypertension that results from elevated RAS activity. COX-2-derived prostanoids are thought to exert a vasodilatory influence on the vasculature to help counteract the effects of Ang-II-induced vasoconstriction. However, studies in hypertensive rats reported that COX-2 inhibition either decreases [42] or does not affect arterial pressure [43, 44] . Arterial pressure in the aortic coarctation model decreased with COX-2 inhibition in association with decreased PRA suggesting that inhibition of renin release may be responsible [45] . COX-2 inhibition did not augment the reduction in arterial pressure elicited by losartan [46] . Further, the blood pressure lowering effects of furosemide were neutralized by COX-2 inhibition [47] . These results and emerging evidence suggest a COX-2 prohypertensive effect that has been underappreciated. Nonselective COX inhibition lowered blood pressure without affecting renin release in Cx40 À/À mice, whose genetic alteration manifests a renin-dependent hypertension [48] . In chronic Ang-II-infused mice in which renin levels are suppressed, COX-2 inhibition also decreased blood pressure [31 && ]. These studies suggest that COX-2 contributes to the hypertension independently of the renin or Ang II levels.
The effects of selective COX-2 blockade with nimesulide on blood pressure and renal hemodynamics were evaluated in transgenic rats [TGR (Cyp1a1-Ren2)] with inducible Ang-IIdependent malignant hypertension [6] . In this model, the plasma renin levels are maintained independent of macula densa renin release. Similar to the responses in salt-restricted rats, COX-2 inhibition led to pronounced decreases in both GFR and RPF, indicating that the enhanced intrarenal COX-2-derived vasodilator metabolites buffer the vasoconstrictor action of Ang II in the kidney and play an important role in maintaining RPF and GFR (Fig. 3) . However, COX-2 inhibition decreased arterial pressure, indicating that the systemic COX-2derived metabolites are vasoconstrictive and contribute to the development of hypertension. Similarly, COX-2 inhibition during conditions of neuronal nitric oxide synthase (nNOS) blockade decreased arterial pressure in Cyp1a1-Ren2 rats but increased renal vascular resistance in hypertensive Cyp1a1-Ren2 transgenic rats indicating independence from nitric oxide actions [5] . Thus, elevated arterial blood pressure is due, at least in part, to increased systemic vasoconstrictor prostanoids generated by the COX-2 enzymatic pathway.
Recent studies reveal oxidative stress as a participant in COX-2-mediated elevation of blood pressure. Local activation of RAS activity, via increased reactive oxygen species (ROS) generation, mediates glomerular COX-2 upregulation during chronic Ang II infusions [49] and in hypertensive salt-sensitive rats [50] . Further, ROS might alter the relationship between COX-2 and Ang II from antagonistic to cooperative with regard to the blood pressure effects. The effect of COX-2 inhibition to lower blood pressure in transgenic rats has been attributed to oxidative stress [51] , though this dependence has not been consistently demonstrated [52] . These recent experiments suggest the potential for ROS to tip the consequence of COX-2 activity away from attenuating Ang II renovascular resistance regulation and towards augmenting renal inflammation and generation of hypertension.
DIABETIC NEPHROPATHY: MORE THAN COX-2 DYSREGULATION OF HEMODYNAMICS
COX inhibitors attenuate the development of experimental diabetic nephropathy in rats [53] . Further, COX-2-mediated effects have been implicated in diabetic nephropathy in animal models of diabetes and human diabetic patients. Selective COX-2 inhibition reduces proteinuria in renal patients without reducing systolic blood pressure [54] . Acute and chronic COX-2 inhibition prevents hyperfiltration in diabetic rats and markedly reduces albuminuria independently of changes in plasma glucose levels [55 && ]. Interestingly, changes in RPF have not consistently paralleled the GFR responses to COX-2 inhibition [56, 57] , raising the possibility of nonvascular-dependent influences of COX-2 inhibitors on GFR. Glomerular effects of COX-2 are supported by the fact that macula densa COX-2 expression peaks at a time earlier than glomerular COX-2 [58] . Hyperglycemia augments COX-2-mediated hyperfiltration but lessens the ability of COX-2 to increase GFR in hyperfiltering patients [56] and might signify increased compromise of the glomerular barrier (in addition to vasodilation) mediated by COX-2. Increased expression of COX-2 in nonmacula densa cells and podocytes has been previously demonstrated in a streptozotocin diabetic model [57] . Whereas basal COX-2 may be important for podocyte survival, overexpression of podocyte COX-2 increases susceptibility to podocyte injury, possibly via activation of thromboxane receptors [7] . In addition, the hyperfiltration mediated by COX-2 may also contribute to damage of podocytes in that sheer stress increases podocyte COX-2 expression and PGE 2 production [59 && ]. Activation of the EP4 receptor has been linked to increased PGE 2 production, thus potentially mediating a positive feedback in the course of kidney injury similar to that observed in diabetes. Early after 5/6 nephrectomy, the urinary albumin-creatinine excretion ratio of mice with kidney selective podocyte overexpression of the EP4 receptor was significantly higher than in nontransgenic mice [8 & ]. There is also evidence that COX-2 is a primary mediator of renal injury attributed to RAS activity during hyperglycemia associated with diabetes. In female diabetic patients, Ang-II-mediated reductions in GFR were abolished by COX-2 inhibition [60] . Glomerular COX-2 expression is correlated with glomerular sclerosis to a higher degree than renin positivity [58] . Studies also show association between RAS activity and COX-2 expression. Prorenin receptor (PRR) overexpression augments cortical COX-2 expression [61] . The relevance of diabetes on RAS promotion of COX-2 activity is demonstrated by the finding that glucose increases mesangial cell COX-2 via the AT 1 receptor [62] as well as renin and PRR [63 & ]. Though reactive oxygen species have been implicated in mediating glucose and Ang II augmentation of COX-2 expression in glomerular endothelial cells [64 & ], the mechanism remains to be fully elucidated.
CONCLUSION
Interactions between the RAS and COX-2 metabolites converge on the kidney through regulation of renin release, renal hemodynamics, and excretory function. Recent experiments have revealed a role for COX-2 in the promotion and restriction of the RAS. On one hand, COX-2 metabolites mediate renin release via the EP4 receptor. On the other hand, COX-2 metabolites limit the resulting Ang-II-mediated increases in renovascular resistance by eliciting direct vasodilation and opposing COX-1/ Ang II vascular effects. These studies reveal the potential conversion of COX-2-mediated beneficial actions to a dysfunctional regulator of the RAS involving mechanisms that potentiate Ang II hypertension and kidney injury. Emerging studies implicate oxidative stress in the transition to COX-2 pro-hypertensive effects. Hyperglycemia also appears to transform COX-2 maintenance of hemodynamics to pathophysiologic degradation of the glomerular integrity via a PRR-COX-2-EP4 receptor positive feedback loop. An expanded assessment of prostaglandin synthase and specific receptors may reveal strategies to exploit renal COX-2 activity to ameliorate Ang-II-mediated hypertensive and diabetic kidney diseases. 
